Akebia Therapeutics Signs Material Definitive Agreement
Ticker: AKBA · Form: 8-K · Filed: Oct 16, 2024 · CIK: 1517022
| Field | Detail |
|---|---|
| Company | Akebia Therapeutics, Inc. (AKBA) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, partnership
Related Tickers: AKBA
TL;DR
Akebia just signed a big deal, details TBD.
AI Summary
On October 15, 2024, Akebia Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its counterparty, or any associated financial terms.
Why It Matters
This filing indicates a significant new contract or partnership for Akebia Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement.
Key Players & Entities
- Akebia Therapeutics, Inc. (company) — Registrant
- October 15, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Akebia Therapeutics?
The filing states that Akebia Therapeutics, Inc. entered into a material definitive agreement on October 15, 2024, but does not provide specific details about its nature.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the other party involved in the material definitive agreement.
Are there any financial terms or obligations associated with this agreement mentioned in the filing?
No specific financial terms or obligations related to the material definitive agreement are detailed in this Form 8-K filing.
When was this material definitive agreement entered into?
The agreement was entered into on October 15, 2024.
What is the purpose of this Form 8-K filing for Akebia Therapeutics?
The purpose of this Form 8-K filing is to report the entry into a material definitive agreement by Akebia Therapeutics, Inc.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2024-10-16 07:36:10
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share AKBA The Nasdaq Capital Marke
Filing Documents
- akba-20241015.htm (8-K) — 28KB
- 0001517022-24-000067.txt ( ) — 163KB
- akba-20241015.xsd (EX-101.SCH) — 2KB
- akba-20241015_def.xml (EX-101.DEF) — 4KB
- akba-20241015_lab.xml (EX-101.LAB) — 24KB
- akba-20241015_pre.xml (EX-101.PRE) — 14KB
- akba-20241015_htm.xml (XML) — 3KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on February 10, 2021, Akebia Therapeutics, Inc. (the "Company") entered into a Supply Agreement with STA Pharmaceutical Hong Kong Limited, a Hong Kong corporation ("STA") (the "Supply Agreement"), under which STA manufactures vadadustat drug product ("Product") for the Company. On October 15, 2024, the Company and STA entered into Amendment #1 to the Supply Agreement (the "Amendment"). Pursuant to the Amendment, the term of the Supply Agreement is extended until January 1, 2032. In addition, the Amendment amends the volume-based pricing structure and certain other provisions related to the Product under the Supply Agreement. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which the Company expects to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AKEBIA THERAPEUTICS, INC. Date: October 16, 2024 By: /s/ John P. Butler Name: John P. Butler Title: President and Chief Executive Officer